Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701223 | 0.91 | LPAR3 (0.50) | LPAR3LPAR2ALDH1A1LMNAMAPT | |
| SCHEMBL5701235 | 0.83 | LPAR3 (0.44) | LPAR3LPAR2ALDH1A1LMNAMAPT | |
| SCHEMBL11316419 | 0.82 | LPAR3 (0.53) | LPAR3LPAR2ALDH1A1LMNAMAPT | |
| SCHEMBL4285702 | 0.82 | LPAR3 (0.53) | LPAR3LPAR2ALDH1A1LMNAMAPT | |
| SCHEMBL9701578 | 0.80 | PPARD (0.52) | LPAR3LPAR2ALDH1A1LMNAMAPT | |
| SCHEMBL6688623 | 0.77 | LPAR3 (0.56) | LPAR3LPAR2CETP | |
| SCHEMBL5701289 | 0.77 | LPAR3 (0.56) | LPAR3LPAR2CETP | |
| SCHEMBL5701297 | 0.76 | GABBR2 (0.48) | ALDH1A1LMNATSHRCYP3A4RECQL | |
| SCHEMBL5701186 | 0.76 | LPAR3 (0.54) | LPAR3LPAR2CETP | |
| SCHEMBL22322204 | 0.75 | LPAR3 (0.52) | LPAR3LPAR2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109184-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1485391-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20040019020-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019020-A1 | Phosphate transport inhibitors | SLC34A2, SLC43A1, SLC34A1 | LPAR3 2860/4885LPAR2 2181/4885ALDH1A1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.